Getting your player ready...
Biopharmaceutical company Pharmion said its shareholders have approved a $2.9 billion cash-and-stock buyout offer from rival Celgene Corp.
Pharmion shareholders voted Thursday to approve the sale, and the companies said it should close today. Pharmion shareholders will receive $72 per share in cash and stock.
New Jersey-based Celgene is engaged primarily in the development of therapies for the treatment of cancer and inflammatory diseases. Pharmion is researching and developing products for the treatment of hematology and oncology patients.
